Sharon Bio-Medicine Ltd (SHARONBIO) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 532908 | NSE: SHARONBIO | Pharmaceuticals & Drugs | Small Cap

BSE Share Price
Not Listed

Sharon Bio-Medicine Ltd (SHARONBIO) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 532908 | NSE: SHARONBIO | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Sharon Bio-Medicine

Based on:

M-Cap below 100cr DeciZen not available

Sharon Bio-Medicine stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
0.10
Market Cap:
1.9 Cr.
52-wk low:
3.1
52-wk high:
4.7

Is an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Sharon Bio-Medicine:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Value Creation Index Colour Code Guide

Jun'12Jun'13Jun'14Jun'15Mar'16Mar'17Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 14.1%13.8%14.7%-12.8%-27.7%-77.2%4.3%9.8%43.2%25.2%-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 7851,0601,314834338139188192190197190
Sales YoY Gr.-35%24%-36.5%-59.5%-58.9%35.7%2%-1%3.8%-
Adj EPS 3.956.6-14.5-27.9-28.429.230.836,496.68,238.533
YoY Gr.-27.2%31.5%-319.7%NANANA5.6%118433.9%-77.4%-
BVPS (₹) 13.117.924.18-22.9-46.7-1,130-1,068.110,056.419,532.4-1,161.5
Adj Net
Profit
41.652.969.6-172-332-33816.817.787.519.819
Cash Flow from Ops. -53-70.2-69.5-81.9-37.633.92341.166.938.2-
Debt/CF from Ops. -9.6-9.2-10.4-10.1-29.721.43620.12.13.2-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -14.2%-10.2%1.6%3.8%
Adj EPS 133.8%NA556.1%-77.4%
BVPS125.3%NANA94.2%
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Jun'12Jun'13Jun'14Jun'15Mar'16Mar'17Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
21.324.223.7-74.6786.291.8-2.9-2.9-29.753.40.4
Op. Profit
Mgn %
12.111.412-4.1-52.8-220.213.912.514.422.113.3
Net Profit
Mgn %
5.355.3-20.7-98.3-243.78.99.2461010
Debt to
Equity
3.73.42.98.7-4.1-1.3-1.3-1.45.62.5-
Working Cap
Days
203198202322761586164190154150161
Cash Conv.
Cycle
1671651692726574679314378-160

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Sharon Bio-Medicine Ltd.

Standalone Consolidated
TTM EPS (₹) 33 -406.4
TTM Sales (₹ Cr.) 190 838
BVPS (₹.) -1,161.5 -394.2
Reserves (₹ Cr.) -670 -228
P/BV 0.00 -0.01
PE 0.10 0.00
From the Market
52 Week Low / High (₹) 3.10 / 4.65
All Time Low / High (₹) 2.60 / 90.20
Market Cap (₹ Cr.) 1.9
Equity (₹ Cr.) 1.2
Face Value (₹) 2
Industry PE 40.7

Management X-Ray of Sharon Bio-Medicine:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Sharon Bio-Medicine - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Sharon Bio-Medicine

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSJun'12Jun'13Jun'14Jun'15Mar'16Mar'17Mar'22Mar'23Mar'24Mar'25
Sales785.061,059.501,313.77833.95253.45138.81188.39192.22190.23197.48
Operating Expenses 689.78939.011,156.71868.34387.29444.48162.19168.20162.80153.87
Manufacturing Costs9.9710.7412.4319.4714.1112.4828.6324.6839.6337.94
Material Costs655.97902.081,112.75808.50332.25237.4084.4492.9071.1867.77
Employee Cost 13.9714.3118.8719.8316.5521.2930.5933.2935.7937.11
Other Costs 9.8711.8812.6620.5524.39173.3218.5217.3316.1911.04
Operating Profit 95.28120.49157.06-34.38-133.84-305.6826.2024.0127.4343.61
Operating Profit Margin (%) 12.1%11.4%12.0%-4.1%-52.8%-220.0%13.9%12.5%14.4%22.1%
Other Income 0.930.891.682.631.9519.852.814.4663.987.76
Interest 34.2643.0658.6393.6470.9829.870.110.0610.3411.58
Depreciation 8.8612.1315.3519.1715.0116.1211.239.409.708.77
Exceptional Items -0.0300-76.64-71.35-13.700000
Profit Before Tax 53.0566.1984.75-221.20-289.24-345.5217.6719.0171.3731.03
Tax 11.4413.3315.144.669.972.3400-19.037.85
Profit After Tax 41.6152.8669.62-225.86-299.20-347.8617.6719.0190.4023.18
PAT Margin (%) 5.3%5.0%5.3%-27.1%-118.0%-250.0%9.4%9.9%47.5%11.7%
Adjusted EPS (₹)3.95.06.6-19.0-25.2-29.330.733.036,159.29,271.6
Dividend Payout Ratio (%)5%3%5%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSJun'12Jun'13Jun'14Jun'15Mar'16Mar'17Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 138.17189.18263.39104.36-195.21-555.57-609.22-614.6925.1448.83
Share Capital 10.5610.5621.1123.7923.7923.791.151.150.010.01
Reserves 127.61178.62242.2780.57-219-579.36-610.37-615.8425.1448.83
Minority Interest0000000000
Debt507.54643.89725.38824.41836.32727.19827.32827.32140.67122.93
Long Term Debt238.64280.87291.42522.57543.60496.79558.02558.02140.67122.93
Short Term Debt268.89363.02433.96301.84292.72230.41269.31269.3100
Trade Payables49.6759.8661.1751.2740.0342.3243.4644.3816.4019.05
Others Liabilities 78.6579.01111.6931.4841.70139.6637.5733.962.4311.41
Total Liabilities 774.03971.931,161.631,011.53722.84353.60299.14290.98184.64202.22

Fixed Assets

Gross Block235.62317.87380.87406.69408.15405.48398.66432.12222.87226.83
Accumulated Depreciation34.2946.3355.8574.5889.60114.40264.02318.93113.24118.40
Net Fixed Assets 201.33271.55325.02332.10318.56291.08134.64113.19109.63108.44
CWIP 59.9042.8214.930000.150.201.801.51
Investments 3.983.981.231.040.0600000
Inventories196.22260.24322.45301.42179.9921.0342.3339.0225.4335.43
Trade Receivables260.12355.10414.31315.02183.1821.6226.8826.0927.9540.11
Cash Equivalents 6.286.2712.2716.0110.165.7751.6389.990.290.17
Others Assets 46.2031.9871.4145.9430.9014.1043.5122.4819.5316.57
Total Assets 774.03971.931,161.631,011.53722.84353.60299.14290.98184.64202.22

Cash Flow

(All Figures are in Crores.)
PARTICULARSJun'12Jun'13Jun'14Jun'15Mar'16Mar'17Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity -52.98-70.23-69.47-81.91-28.2133.9222.9641.1166.9238.17
PBT 53.0566.1984.75-144.56-217.89-345.5217.6719.0171.3731.03
Adjustment 32.6841.9259.2031.964.04219.2110.138.44-35.3418.76
Changes in Working Capital -104.73-135.56-154.8124.34256.62189.77-5.1913.1330.46-11.82
Tax Paid 000000.3300.540.430.20
Cash Flow From Investing Activity -61.24-64.28-27.38-10.060.14-1.38-3.24-2.77-8.09-8.99
Capex -62.07-65.17-31.81-10.89-1.47-1.51-4.51-4.99-8.99-10.67
Net Investments -0.1002.750.200.970000-0.06
Others 0.930.891.680.630.640.121.262.210.901.74
Cash Flow From Financing Activity 116.66134.50102.8595.7022.22-36.930.030.02-148.53-29.36
Net Proceeds from Shares 00066.830000548.460
Net Proceeds from Borrowing 00000000-417.35-17.74
Interest Paid 00000-1.8900-10.33-11.57
Dividend Paid -1.90-1.58-3.800000000
Others 118.56136.08106.6528.8722.22-35.030.030.02-269.31-0.05
Net Cash Flow 2.44-0.0163.73-5.85-4.3919.7438.36-89.70-0.17

Finance Ratio

PARTICULARSJun'12Jun'13Jun'14Jun'15Mar'16Mar'17Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)29.5832.3731.44-129.46N/AN/AN/AN/A062.67
ROCE (%)14.0613.7614.73-12.8N/AN/AN/AN/A43.1825.24
Asset Turnover Ratio1.151.211.230.770.290.260.370.650.81.02
PAT to CFO Conversion(x)-1.27-1.33-1N/AN/AN/A1.32.160.741.65
Working Capital Days
Receivable Days105106107160359266203505263
Inventory Days827981137347261215776256
Payable Days22222025506318017315695

Sharon Bio-Medicine Ltd Stock News

Sharon Bio-Medicine Ltd FAQs

The current trading price of Sharon Bio-Medicine on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Sharon Bio-Medicine stood at ₹1.85.
The latest P/E ratio of Sharon Bio-Medicine as of 31-Dec-1969 is 0.10.
The latest P/B ratio of Sharon Bio-Medicine as of 31-Dec-1969 is 0.00.
The 52-week high of Sharon Bio-Medicine is ₹4.65 and the 52-week low is ₹3.10.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Sharon Bio-Medicine is ₹190.2 ( Cr.) .

About Sharon Bio-Medicine Ltd

Sharon Bio-Medicine, established in 1989, is into manufacturing and supply of Active Pharmaceutical Ingredients (APIs).

The company has established its name as a reliable supplier of intermediates. In international markets, the company serves Latin America, Middle East, South East Asia and SAARC countries. With the setting up of new facilities Sharon has geared up to enter other markets such as Europe, Japan, Australia and USA in the next two years.

With setting and successful commercialisation of the solid dosage formulation facility at Dehradun, its formulations are now being marketed in Africa, Latin America and other markets.

The company’s research team constantly seeks development of non-infringing routes for APIs in therapeutic segments like cardiovascular diseases and anti-ulcerants.

It also offers contract manufacturing for finished dosage forms; viz. tablets, capsules and injectables. Sharon has identified niche areas of oncology for export markets.

Products

  • APIs and Pellets
  • Intermediates
  • Formulations

Milestones

  • 1995 - The current management took over and started manufacturing of pharma intermediates
  • 1997 - The company started manufacturing APIs and launched its first drug -- trimetazidine di hydrochloride -- a cardiovascular drug.
  • 2000 - The company came out with public offering of 25% stake. The issue was oversubscribed by 3.85 times. It set up a R&D block to carry out process synthesis for APIs and intermediates.
  • 2005 - The company received ISO 9001-2000 accreditation by BVQI-UKAS and BVQI-ANAB
  • 2006 - It started construction of a state-of-the-art formulation unit for oral solid dosages at Dehradun, New Delhi with an estimated cost of $8 million.
  • 2007 - The company commissioned its formulation plant. It also started supplying formulations to reputed pharmaceutical companies in India on contract manufacturing basis.
  • 2009 - The company set up and operationalised a new business division by name SA-Ford dedicated to toxicology studies. It also set up and operationalised a state-of-the-art API plant at Taloja, near Mumbai, which enables it to offer a wide variety of services to its customers.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×